Already in the beginning of the year 2000, several studies suggested that interleukin (IL)-17 plays a key role in the destruction of beta cells and the development of type 1 diabetes.7, 15 In the Ixekizumab Diabetes Intervention Trial (I-DIT), we aim to evaluate if endogenous insulin secretion can be preserved or increased in people with newly diagnosed type 1 diabetes by inhibition of IL-17 compared with placebo in addition to their conventional therapy. Here, INS is linked to type 1 diabetes mellitus.